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 Abstract 
 
Background: In recent years, there has been increasing scientific interest into the effects and 
pharmacology of serotonergic hallucinogens.  While a large amount of experimental work has 
been conducted to characterize the behavioral response to hallucinogens in rodents, there has 
been little systematic investigation of mescaline and its analogs.  The hallucinogenic potency of 
mescaline is increased by α-methylation and by homologation of the 4-methoxy group but it not 
clear whether these structural modifications have similar effects on the activity of mescaline in 
rodent models.  Methods: In the present study, the head twitch response (HTR), a 5-HT2A 
receptor-mediated behavior induced by serotonergic hallucinogens, was used to assess the effects 
of mescaline and several analogs in C57BL/6J mice.  HTR experiments were conducted with 
mescaline, escaline (4-ethoxy-3,5-dimethoxyphenylethylamine) and proscaline (3,5-dimethoxy-
4-propoxyphenylethylamine), their α-methyl homologues TMA (3,4,5-trimethoxyamphetamine), 
3C-E (4-ethoxy-3,5-dimethoxyamphetamine) and 3C-P (3,5-dimethoxy-4-propoxy-
amphetamine), and the 2,4,5-substituted regioisomers TMA-2 (2,4,5-trimethoxyamphetamine), 
MEM (4-ethoxy-2,5-dimethoxyamphetamine) and MPM (2,5-dimethoxy-4-
propoxyamphetamine).  Results: TMA induced the HTR and was twice as potent as mescaline.  
For both mescaline and TMA, replacing the 4-methoxy substituent with an ethoxy or propoxy 
group increased potency in the HTR assay.  By contrast, although TMA-2 also induced the HTR 
with twice the potency of mescaline, potency was not altered by homologation of the 4-alkoxy 
group in TMA-2.  Conclusions: The potency relationships for these compounds in mice closely 
parallel the human hallucinogenic data.  These findings are consistent with evidence that 2,4,5- 
and 3,4,5-substituted phenylalkylamine hallucinogens exhibit distinct structure-activity 
relationships.  These results provide additional evidence that the HTR assay can be used to 
investigate the SAR of serotonergic hallucinogens.   
 
Keywords: psychedelic, head shake, phenylisopropylamine, phenethylamine, animal model. 
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Introduction 
 
Mescaline (3,4,5-trimethoxyphenylethylamine), the active constituent of the peyote 
cactus (Lophophora williamsii), is considered to be a prototypical serotonergic hallucinogen.    
The first report describing the hallucinogenic effects of mescaline was published by Dr. Arthur 
Heffter based on self-experiments (Heffter, 1898).  Although mescaline has a fairly low potency, 
with 178–356 mg of the hydrochloride salt being the usual dosage range in humans (Shulgin and 
Shulgin, 1991), addition of an α-methyl group (Shulgin et al., 1961) or replacement of the 4-
methoxy group with an ethoxy or propoxy group (Shulgin, 1978) produces a significant increase 
in potency.  Potency is also increased by rearranging the substituents from a 3,4,5-pattern to a 
2,4,5-pattern (Shulgin, 1964).  The structures of mescaline analogs and their typical dose ranges 
in humans are shown in Figure 1. 
In recent years, there has been increasing scientific interest into the effects and 
pharmacology of serotonergic hallucinogens.  This interest has been driven, in part, by evidence 
hallucinogens may possess therapeutic efficacy in a variety of disorders including anxiety, 
depression, and substance abuse (Griffiths et al., 2016; Ross et al., 2016; Carhart-Harris et al., 
2016; Johnson et al., 2014; Grob et al., 2011).  Although human trials with these substances all 
but ceased after the 1960s, these investigations have cautiously resumed during the last decade. 
Another reason for the renewed focus on serotonergic hallucinogens is the large number 
available as recreational drugs (Gatch et al., 2017; Blough et al., 2014; Brandt et al., 2017b; 
Klein et al., 2018; Brandt et al., 2016; Halberstadt et al., 2018a).  Mescaline and its α-methyl 
derivative 3,4,5-trimethoxyamphetamine (TMA) are listed on the United Nations 1971 
Convention on Psychotropic Substances.  A variety of mescaline analogs have been encountered 
in Europe, including escaline (3,5-dimethoxy-4-ethoxyphenethylamine), proscaline (3,5-
dimethoxy-4-propoxyphenethylamine), 3C-E (4-ethoxy-3,5-dimethoxyamphetamine), 3C-P (3,5-
dimethoxy-4-propoxyamphetamine), and TMA-2 (2,4,5-trimethoxyamphetamine) (King, 2014; 
EMCDDA, 2004).  TMA-2 was first detected in 1999 (EMCDDA, 2004) and escaline, 
proscaline, 3C-E and 3C-P were detected in 2013 (EMCDDA, 2014).  The identification of 
escaline has also been reported by researchers in Japan (Kaizaki-Mitsumoto et al., 2016).  
Another related substance, MEM (4-ethoxy-2,5-dimethoxyamphetamine), appeared as a street 
drug in Canada in 1986 (Dawson and Awdovich, 1987).  Given the potential use of 
hallucinogens as therapeutic agents and their continuing use, it is necessary to define the 
pharmacology and structure-activity relationships (SAR) of these substances.   
Although rodent behavioral models are routinely used to evaluate the SAR of 
hallucinogenic drugs (Nichols, 2018; Halberstadt and Geyer, 2018), there has been little 
systematic investigation of mescaline analogs in laboratory studies.  Mescaline has been tested in 
a number of drug discrimination (DD) studies (e.g., Glennon and Young, 1982; McLean et al., 
2006; Hirschhorn and Winter, 1971; Schechter and Rosecrans, 1972).  TMA, TMA-2, and MEM 
produced full substitution in rats trained to discriminate the hallucinogen 2,5-dimethoxy-4-
methylamphetamine (DOM) from saline (Glennon et al., 1982; Glennon and Young, 1982).  
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Conversely, escaline, the 4-ethoxy homolog of mescaline, did not substitute in LSD-trained rats 
(Monte et al., 1997).  The latter finding is surprising because escaline is a hallucinogen in man 
(Shulgin and Shulgin, 1991).   
The goal of the present investigation was to assess the behavioral effects of mescaline 
and several analogs using the head twitch response (HTR) assay.  Serotonergic hallucinogens 
induce the HTR, a brief paroxysmal head rotation in rats and mice, via activation of the 5-HT2A 
receptor (Schreiber et al., 1995; Canal and Morgan, 2012; Halberstadt and Geyer, 2014; 
Halberstadt et al., 2011), which is the site associated with the psychedelic effects of 
hallucinogens in humans (Valle et al., 2016; Kraehenmann et al., 2017; Preller et al., 2017; 
Kometer et al., 2013; Vollenweider et al., 1998).  The HTR is used as a behavioral proxy in 
rodents for human hallucinogenic effects because it can reliably distinguish hallucinogenic and 
non-hallucinogenic 5-HT2A receptor agonists (Gonzalez-Maeso et al., 2007).  Although 
mescaline and TMA induce the HTR in rodents (Corne and Pickering, 1967; Silva and Calil, 
1975), other phenylalkylamines with a 3,4,5-substitution pattern have not been evaluated.  Given 
the results of the DD studies, it is important to determine whether escaline can induce the HTR.  
In addition, it is not clear whether the activity of mescaline analogs in the HTR assay is affected 
by structural modifications known to alter the potency of 3,4,5-trialkoxyphenethylamines in 
humans.  HTR studies were conducted with mescaline analogs in C57BL/6J mice to examine the 
effect of the following structural modifications: (a) homologation of the 4-position alkoxy group; 
(b) addition of an α-methyl group; and (c) relocation of the ring-substituents from a 3,4,5- to a 
2,4,5-substitution pattern.  The mescaline analogs produced LSD-like behavioral effects in vivo 
and their relative potencies were consistent with human data.   
	
Materials and Methods 
 
Animals 
 
 Male C57BL/6J mice (6-8 weeks old) obtained from Jackson Laboratories (Bar Harbor, 
ME, USA) were housed in a vivarium at the University of California San Diego, an AAALAC-
approved animal facility that meets all Federal and State requirements for care and treatment of 
laboratory animals.  Mice were housed up to four per cage in a climate-controlled room on a 
reverse-light cycle (lights on at 1900 h, off at 0700 h) and were provided with ad libitum access 
to food and water, except during behavioral testing.  Testing was conducted between 1000 and 
1800 h.  All animal experiments were carried out in accordance with NIH guidelines and were 
approved by the UCSD Institutional Animal Care and Use Committee.  
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Drugs 
 
 Mescaline hydrochloride was obtained from Sigma Chemical Co. (St. Louis, MO, USA). 4-
Ethoxy-3,5-dimethoxyphenethylamine (escaline) hydrochloride, 3,4,5-trimethoxyamphetamine 
(TMA) hydrochloride, and 2,4,5-trimethoxyamphetamine (TMA-2) freebase were obtained from 
Cayman Chemical (Ann Arbor, MI, USA). 3,5-Dimethoxy-4-propoxyphenethylamine 
(proscaline) hydrochloride was obtained from Enamine Ltd. (Monmouth Junction, NJ, USA). 4-
Ethoxy-3,5-dimethoxyamphetamine (3C-E) hydrochloride, 3,5-dimethoxy-4-
propoxyamphetamine (3C-P) hydrochloride, and 4-ethoxy-2,5-dimethoxyamphetamine (MEM) 
hydrochloride were available from earlier studies. 4-Propoxy-2,5-dimethoxyamphetamine 
(MPM) trifluoroacetate was synthesized in the laboratory of Jesper L. Kristensen, PhD.  The 
identity and analytical purity of the test substances were confirmed by mass spectrometry and 
nuclear magnetic resonance spectroscopy. Test substances were dissolved in isotonic saline and 
injected intraperitoneally (IP) at a volume of 5 mL/kg.  	
 
Head Twitch Response Studies 
 
 The head twitch response (HTR) was assessed using a head-mounted magnet and a 
magnetometer detection coil (Klein et al., 2018; Nichols et al., 2015; Halberstadt and Geyer, 
2013; Halberstadt and Geyer, 2014).  Briefly, mice were anesthetized, a small incision was made 
in the scalp, and a small neodymium magnet was attached to the dorsal surface of the cranium 
using dental cement.  Following a two-week recovery period, HTR experiments were carried out 
in a well-lit room with at least 7 days between sessions to avoid carryover effects. Test 
compounds were injected immediately prior to testing.  Mice (n = 5–7/group) were injected with 
drug or vehicle and then HTR activity was recorded in a glass cylinder surrounded by a 
magnetometer coil for 30 min.  Coil voltage was low-pass filtered (2–10 kHz cutoff frequency), 
amplified, digitized (20 kHz sampling rate, 16-bit ADC resolution), and saved to disk using a 
Powerlab/8SP data acquisition system with LabChart software ver. 7.3.2 (ADInstruments, 
Colorado Springs, CO, USA), then filtered off-line (40–200 Hz band-pass).  Head twitches were 
identified manually based on the following criteria: 1) sinusoidal wavelets; 2) evidence of at least 
three sequential head movements (usually exhibited as bipolar peaks) with frequency ≥ 40 Hz; 3) 
amplitude exceeding the level of background noise; 4) duration < 0.15 s; and 5) stable coil 
voltage immediately preceding and following each response. 
 After magnet implantation, mice were tested in multiple HTR experiments, for up to 4–5 
months.  Repeated administration of hallucinogens at weekly intervals does not produce 
tolerance in the HTR paradigm (Smith et al., 2014; Rangel-Barajas et al., 2014; Gewirtz and 
Marek, 2000).  We have confirmed that experimental results obtained using these procedures are 
stable and replicable over time, both within single cohorts of mice and across multiple 
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independent cohorts.  Individual experiments were performed between-subjects, with 
pseudorandomized group assignments, which further reduces the likelihood of carryover effects.  
  
 
Data Analysis 
 
 The entire 30-min recordings were examined for head twitches.  Head twitch counts were 
analyzed using one-way analyses of variance (ANOVA).  Post hoc pairwise comparisons 
between selected groups were performed using Tukey's studentized range method.  Significance 
was demonstrated by surpassing an α-level of 0.05.   
 Median effective doses (ED50 values) and 95% confidence intervals (95% CI) for HTR 
dose-response experiments were calculated by nonlinear regression (Prism 7.00, GraphPad 
Software, San Diego, CA, USA).  A Gaussian distribution (Christopoulos et al., 2001) was used 
to fit biphasic HTR dose-response data: 
	
	 E = Baseline + Range × �
!
!"# [!]!!"#$
!"#$%
!
	
	
	 midA =  logED!" + slope −ln (0.5)	
	
In these equations, E is the drug effect, Baseline is the response in the control group, Range is 
the distance from Baseline to the top of the curve, [A] is the dose of the drug, and midA is the 
logarithm of the dose corresponding to the top of the curve.   
 
 
Results 
 
 The first set of experiments examined the response to phenylethylamines with a 3,4,5-
substitution pattern.  HTR data are shown in Table 1.  Mescaline induced the HTR with an ED50 
of 6.51 mg/kg, which is equivalent to a molar potency of 26.3 µmol/kg.  Similar to other 
hallucinogens (Fantegrossi et al., 2010; Fantegrossi et al., 2005; Fantegrossi et al., 2006; Klein et 
al., 2018; Halberstadt et al., 2018a), the response to mescaline and most of the other compounds 
followed an inverted-U-shaped dose-response function.  Escaline (the 4-ethoxy homologue of 
mescaline) and proscaline (the 4-propoxy homologue) also induced the HTR.  Escaline (ED50 = 
11.2 µmol/kg) and proscaline (ED50 = 8.09 µmol/kg) were two and three times as potent as 
mescaline, respectively.  Figure 2 shows the time-dependence of the responses induced by 
mescaline, escaline and proscaline.   
 The second set of experiments evaluated the effect of α-methylation on the activity of 
mescaline and its homologs.  TMA, the α-methyl derivative of mescaline, induced the HTR with 
an ED50 of 13.6 µmol/kg, making it twice as potent as mescaline.  The two higher 4-alkoxy 
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homologues 3C-E (α-methylescaline; ED50 = 8.54 µmol/kg) and 3C-P (α-methylproscaline; ED50 
= 8.47 µmol/kg) were essentially equipotent and both had 50% higher potency than TMA.  
Figure 3 shows the time-dependence of the responses induced by TMA, 3C-E and 3C-P.   
We also examined whether in vivo potency is affected by relocating the groups on the 
aromatic ring from the 3,4,5-substitution pattern to the 2,4,5-orientation.  Phenylisopropylamines 
(amphetamines) were used for these experiments because 2,4,5-trisubstituted phenylethylamines 
containing an alkoxy group in the 4-position are only weakly active in man and other species.  
For example, a 300 mg oral dose of 2,4,5-trimethoxyphenylethylamine reportedly produced a 
placebo-like response in a self-experiment (Dittrich, 1971).  2,4,5-Trimethoxyphenylethylamine 
also has limited behavioral activity in rats (Smythies et al., 1967).  TMA-2 induced the HTR 
with an ED50 value of 12.4 µmol/kg, making it slightly more potent than TMA.  Replacing the 4-
methoxy group in TMA-2 with an ethoxy or propoxy group had no effect on potency in the HTR 
assay: MEM induced the HTR with an ED50 = 13.6 µmol/kg, whereas the ED50 for MPM was 
12.1 µmol/kg.  Figure 4 shows the time-dependence of the responses induced by TMA-2, MEM 
and MPM.     
 
Discussion 
 
The present investigation examined the behavioral effects of phenylalkylamine 
hallucinogens in mice.  While a large amount of experimental work has been conducted over the 
past few decades to characterize the hallucinogenic activity of mescaline analogs in humans 
(Shulgin and Shulgin, 1991), most of these substances have not been tested in rodent behavioral 
assays.  Mescaline and the other phenylalkylamine hallucinogens induced head twitches in mice, 
demonstrating that they produce LSD-like behavioral effects in vivo.  The potency of mescaline 
and other 3,4,5-trimethoxy-substituted phenylalkylamines was enhanced by lengthening the 4-
methoxy group by one or two methylene units.  By contrast, homologation of the 4-position did 
not increase the potency of 2,4,5-trimethoxy-substituted phenylalkylamines.  The potency of 
mescaline was also increased by the addition of an α-methyl group.  Importantly, the potency 
relationships in mice closely parallel the human hallucinogenic data (Shulgin and Shulgin, 1991).  
These findings demonstrate that the mouse HTR assay can be used to study the SAR of 
serotonergic hallucinogens. 
Although we did not identify the receptor mechanism responsible for the response to 
mescaline and other phenylalkylamines in mice, the behavioral effects assessed in this study are 
likely mediated by 5-HT2A receptor activation.  A multitude of studies have demonstrated that 
the 5-HT2A receptor is responsible for the head twitches induced by hallucinogens, whereas other 
serotonin receptors can be blocked without eliminating the response (Schreiber et al., 1995; 
Halberstadt et al., 2011; Halberstadt and Geyer, 2014; Fantegrossi et al., 2010; Vickers et al., 
2001; Gonzalez-Maeso et al., 2007).  Although compounds such as rolipram, [Met
5
]enkephalin, 
and icilin can induce head twitches through non-5-HT2A receptor-dependent mechanisms 
(Przegalinski et al., 1981; Drust et al., 1981), almost all of the compounds examined are known 
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to be active at the 5-HT2A receptor (Monte et al., 1997; Glennon et al., 1984; Glennon et al., 
1992) and are capable of producing DOM-like stimulus effects in rodents (Glennon et al., 
1983a).  Hence, there is little reason to believe that the head twitches induced by these 
compounds are mediated by a mechanism other than 5-HT2A receptor activation.  
As noted above, the present results are consistent with the established SAR for 
phenylalkylamine hallucinogens in humans.  The identity of the 4-position substituent is known 
to play an important role in determining the potency of phenylalkylamines with a 3,4,5-
trialkoxy-substitution pattern.  A 4-ethoxy or a 4-propoxy group increases human hallucinogenic 
potency compared to a 4-methoxy group (Shulgin, 1978; Shulgin and Shulgin, 1991).  Based on 
their typical dose ranges in humans, escaline and proscaline have about five times the potency of 
mescaline (Figure 1).  Likewise, 3C-E has four times the potency of TMA in humans.  
Homologation of the 4-alkoxy group had a similar effect on potency in the mouse HTR assay.  
Escaline had twofold higher potency than mescaline in mice, whereas proscaline had threefold 
higher potency.  Although there was less of a potency difference between TMA and its higher 
homologs, 3C-E and 3C-P clearly had higher potency than TMA in mice.   
It is not clear why the presence of an alkoxy group larger than methoxy in the 4-position 
of 3,4,5-substitued phenylalkylamines increases potency in vivo, but there are several potential 
explanations.  First, the presence of an ethoxy or propoxy group in the 4-position of mescaline 
analogs may have a favorable impact on their pharmacodynamics.  If the 4-alkoxy group projects 
into a complementary hydrophobic region of the binding pocket then its presence may have a 
favorable effect on 5-HT2A receptor binding.  Indeed, escaline (Ki = 2100 nM) reportedly has 
twofold higher affinity than mescaline (Ki = 5500 nM) for [
3
H]ketanserin-labeled 5-HT2A 
receptors in rat frontal cortex homogenates (Monte et al., 1997).  A second potential explanation 
is that ethoxy and propoxy substituents may enhance CNS partitioning.  The central activity of 
hallucinogens is known to be correlated with their lipophilicity (Barfknecht and Nichols, 1975).  
According to Barfknecht and Nichols (1975), the optimum lipophilicity for a series of 
hallucinogenic phenylisopropylamines is logP = 3.14.  Mescaline has a relatively low logP value 
of 0.78, whereas the values for escaline (logP = 1.11) and proscaline (logP = 1.70) are closer to 
the optimum level (Nichols and Dyer, 1977; Nichols et al., 1977). 
In contrast to the potency increase induced by homologation of the 4-methoxy group in 
mescaline and TMA, homologation of the 4-methoxy group in TMA-2 has little effect on 
behavioral potency.  MEM and MPM were equipotent with TMA-2 in our HTR studies (see 
Table 1).  Similar potency relationships have been reported for TMA-2, MEM, and MPM in 
humans (Shulgin, 1978).  In the rat DD assay, MEM is actually less potent than TMA-2 in 
studies using DOM as the training drug (Glennon et al., 1983a).  These findings are consistent 
with previous evidence that the effects of 3,4,5-substituted and 2,4,5-substituted 
phenylalkylamine hallucinogens are governed by different SAR.  These SAR differences are 
apparent when the methoxy groups of phenylalkylamine hallucinogens are constrained into rigid 
dihydrofuran rings (Monte et al., 1996; Monte et al., 1997).  While activity is maintained by 
rigidification of the methoxy groups in 2,4,5-substituted phenylethylamines (Monte et al., 1996), 
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constraining the orientation of the methoxy groups in 3,4,5-substituted phenethylamines is 
detrimental for activity (Monte et al., 1997).  Notably, when mescaline is docked into an in 
silico-activated homology model of the 5-HT2A receptor, it adopts a different binding pose than 
2,4,5-substituted compounds (McLean et al., 2006).  It is therefore possible that homologation of 
the 4-methoxy group does not uniformly affect the activity of 2,4,5- and 3,4,5-trimethoxy-
substituted phenylalkylamines because their alkoxy groups are oriented differently in the binding 
pocket of the 5-HT2A receptor.   
Phenylisopropylamine hallucinogens are typically more potent than their 
phenylethylamine homologues in vivo.   For example, 2C-D and 2C-B have approximately 1/10 
the potency of DOM and DOB, respectively, in humans (Shulgin and Shulgin, 1991).  In 
preclinical studies of phenylalkylamine hallucinogens, the presence of an α-methyl group 
increases in vivo behavioral potency (Glennon et al., 1983b; Monte et al., 1996; Halberstadt et 
al., 2018a) but does not alter 5-HT2A affinity (Johnson et al., 1990; Glennon et al., 1992; Parrish 
et al., 2005).  There are several potential explanations for the potency differences between 
phenylisopropylamines and phenylethylamines.  The α-methyl group likely reduces the 
metabolic lability of the amine side-chain (Nichols et al., 1991).  Phenylisopropylamines are also 
more lipophilic than phenylethylamines, potentially facilitating their CNS penetration.  Indeed, 
while TMA-2 clearly partitions into the CNS after systemic administration, its α-desmethyl 
analog 2,4,5-trimethoxyphenylethylamine could not be detected in the brain after IP 
administration to rats (Cohen et al., 1974).   
The effects of phenylalkylamine hallucinogens in the HTR assay are generally consistent 
with the results of rat DD studies.  The following potency relationships were reported in studies 
using DOM (1.0 mg/kg) as the training drug: TMA-2 (ED50 = 3.59 mg/kg) > TMA (ED50 = 6.34 
mg/kg) > mescaline (ED50 = 14.64 mg/kg) (Glennon et al., 1982; Glennon and Young, 1982).  
Escaline is a notable exception: according to Nichols and colleagues, escaline produced a 
maximum of 50% substitution when tested in rats trained to discriminate LSD from saline 
(Monte et al., 1997).   It is not clear, however, whether escaline is actually a DD false negative or 
alternatively whether its inability to produce full-substitution is a consequence of other factors.  
Some hallucinogens reportedly have particularly steep dose-response functions in DD studies, 
with complete generalization occurring only within a narrow range of doses, making it difficult 
to detect full-substitution (Glennon et al., 1983a).  Nevertheless, as shown in Table 1, escaline 
clearly induces head twitches in mice, demonstrating that it can produce an LSD-like behavioral 
response in a rodent behavioral model.   
Similar to other hallucinogens (Fantegrossi et al., 2010; Fantegrossi et al., 2008; 
Fantegrossi et al., 2005; Fantegrossi et al., 2006; Halberstadt et al., 2018a; Halberstadt et al., 
2018b), the HTR induced by mescaline analogues is non-monotonic, with a marked response 
decrement occurring at high doses.  According to one group, the descending arm of the response 
to the hallucinogen DOI is blocked by the 5-HT2C antagonists RS102221 and SB-242,084 
(Fantegrossi et al., 2010), indicating that the response decrement is mediated by 5-HT2C 
activation.  However, other studies with 5-HT2C antagonists failed to corroborate their findings 
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(Canal et al., 2013; Canal et al., 2010).  Furthermore, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-
cyanophenylethylamine (25CN-NBOH), a 5-HT2A agonist with moderate selectivity over 5-HT2C 
(Jensen et al., 2017; Halberstadt et al., 2016; Hansen et al., 2014), also induces the HTR with a 
biphasic dose-response (Fantegrossi et al., 2015).  The response decrement associated with high 
doses of 25CN-NBOH is not altered by pretreatment with RS102221 (Fantegrossi et al., 2015), 
indicating that the inhibition of the HTR at high hallucinogen doses can occur in the absence of 
activity at 5-HT2C.  It is possible that high levels of 5-HT2A activation may provoke 
countervailing neuronal or behavioral effects that interfere with the expression of the HTR.  
Further work is required to delineate the mechanisms responsible for the biphasic effects of 
hallucinogens on the HTR.   
Although most of the compounds examined have been evaluated in humans, very little is 
known about the effects of 3C-P and MPM.  MPM reportedly has about the same potency as 
MEM and TMA-2 (Shulgin, 1978), which is entirely consistent with the potencies of these 
compounds in the HTR paradigm.  Even less is known about the activity of 3C-P in humans.  
According to websites such as erowid.org and tripsit.me, 3C-P produces hallucinogenic effects, 
but its active dosage range is uncertain.  Nevertheless, in the present studies, 3C-E and 3C-P had 
virtually identical potencies in the HTR assay; it is reasonable to predict that 3C-P would be 
active in humans in the same dosage range as 3C-E.   
In summary, mescaline and several derivatives induced the HTR in mice.  Notably, the 
potencies of these compounds in mice are consistent with their activity in humans (Shulgin and 
Shulgin, 1991).  Although the HTR assay is widely used to determine whether substances have 
hallucinogen-like behavioral profiles (Gonzalez-Maeso et al., 2007), few studies have evaluated 
the relationship between hallucinogen potencies in HTR experiments and their activity in other 
species including humans.  We have now confirmed — at least for one series of 
phenylalkylamine hallucinogens — that the HTR data are consistent with the established SAR 
for activity in humans.  Hence, although head twitches may have limited value as a model of 
hallucinogenesis (Canal and Morgan, 2012), the HTR assay may be useful for investigations of 
the in vivo potency relationships of hallucinogens.  A preliminary regression analysis, including 
7 compounds from the present investigation (mescaline, escaline, proscaline, TMA, 3C-E, TMA-
2 and MEM) and 5 agents tested previously (LSD, AL-LAD, DOB, 2C-B and 2C-I; Halberstadt 
et al., 2018a; Halberstadt and Geyer, 2013; Halberstadt and Geyer, 2014; Brandt et al., 2017a), 
demonstrated that HTR-derived ED50 values are significantly correlated (r = 0.9761, p < 0.0001) 
with human hallucinogenic potency data collected by A.T. Shulgin (Shulgin and Shulgin, 1997; 
Shulgin and Shulgin, 1991).  Studies are currently underway in our laboratory to examine the 
relationship between HTR potency and human hallucinogenic potency for a much larger series of 
compounds.  Importantly, however, the phenylalkylamines examined in these experiments 
clearly produce behavioral effects similar to those of mescaline and other serotonergic 
hallucinogens.  These findings indicate that the psychopharmacology of these compounds in 
humans is likely to be similar to mescaline and LSD.  Ultimately, clinical trials are necessary to 
fully characterize the human psychopharmacology of these compounds. 
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Table 1.  Summary of the head twitch response (HTR) data. 
Compound One-way ANOVA Time 
(min) 
Dose 
(mg/kg) 
N HTR Counts 
(mean ± SEM) 
ED50 mg/kg 
(95% CI) 
ED50 µmol/kg 
(95% CI) 
Mescaline
a
 F(4,23)=7.54, p=0.0005 30 0 6  6.7 ± 1.0 6.51 26.3 
   3.125 5 15.4 ± 3.0 (4.69–9.02) (18.9–36.4) 
   6.25 5 29.6 ± 4.9   
   12.5 6 61.5 ± 8.2 **   
   25 6 37.3 ± 13.4   
Escaline
a
 F(4,22)=14.95, p<0.0001 30 0 7 8.7 ± 2.8 2.94 11.2 
   1.5 5 22.8 ± 4.9 (2.37–3.65) (9.0–14.0) 
   3 5 48.4 ± 6.6 *   
   6 5 92.8 ± 16.4 **   
   12 5 45.4 ± 7.9 *   
Proscaline
a
 F(4,21)=8.55, p=0.0003 30 0 6 8.8 ± 2.2 2.23 8.09 
   1.5 5 37.2 ± 4.4 (1.42–3.10) (5.13–11.2) 
   3 5 56.4 ± 10.6 *   
   6 5 88.2 ± 12.8 **   
   12 5 51.6 ± 16.0 *   
TMA
a
 F(4,22)=6.32, p=0.0015 30 0 7 10.6 ± 1.4 3.57 13.6 
   3 5 26.0 ± 3.6 (2.05–6.19) (7.84–23.6) 
   6 5 44.0 ± 9.8 **   
   12 5 49.8 ± 7.2 **   
   24 5 39.0 ± 9.6 *   
3C-E
a
 F(4,23)=8.56, p=0.0002 30 0 6 9.8 ± 1.8 2.36 8.54 
   1.5 5 22.6 ± 3.9 (1.42–3.10) (6.02–12.1) 
   3 5 55.4 ± 1.7 **   
   6 6 74.3 ± 12.5 **   
   12 6 48.5 ± 13.2 *   
3C-P
a
 F(4,22)=6.31, p=0.0015 30 0 6 8.0 ± 1.6 2.45 8.47 
   1.5 5 26.6 ± 1.9 (1.72–3.51) (5.92–12.1) 
   3 5 33.8 ± 7.0   
   6 6 57.0 ± 13.0 **   
   12 5 25.2 ± 4.3   
TMA-2
b
 F(4,24)=7.26, p=0.0003 30 0 5 11.6 ± 3.7 2.79 12.4 
   1.5 5 23.6 ± 6.2 (1.94–4.01) (8.61–17.8) 
   3 5 38.6 ± 10.1   
   6 5 52.4 ± 6.1 **   
   12 5 60.8 ± 7.1 **   
   24 5 47.4 ± 6.4 *   
MEM
a
 F(4,23)=12.16, p<0.0001 30 0 6 7.2 ± 1.0 3.75 13.6 
   1.5 5 15.2 ± 3.6 (1.88–7.49) (6.80–27.2) 
   3 6 31.5 ± 2.8   
   6 6 52.7 ± 6.1 **   
   12 5 64.8 ± 15.0 **   
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MPM
c
 F(5,27)=5.38, p=0.0015 30 0 6 3.5 ± 0.7 4.44 12.1 
   1.25 5 5.0 ± 1.1 (2.74–7.19) (7.46–19.6) 
   2.5 5 8.2 ± 1.7   
   5 6 15.8 ± 1.7   
   10 6 25.3 ± 3.6 **   
   19 5 23.6 ± 9.8 *   
*p < 0.05, **p < 0.01, significant difference from the vehicle control group (Tukey's test). 
a
Hydrochloride salt; 
b
freebase; 
c
trifluoroacetate salt.
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FIGURES 
 
 
 
Figure 1.  Chemical structures of the hallucinogens tested in these studies.  The typical dose 
ranges used in humans are indicated (data from: Shulgin and Shulgin, 1991; Shulgin, 1978). 
 
 
 
 
Figure 2.  Time-course of the head twitch response induced by mescaline (A) and its 4-position 
homologs escaline (B) and proscaline (C).  Data are presented as group means in 2-min blocks. 
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Figure 3.  Time-course of the head twitch response induced by TMA (A) and its 4-position 
homologs 3C-E (B) and 3C-P (C).  Data are presented as group means in 2-min blocks. 
 
 
 
 
Figure 4.  Time-course of the head twitch response induced by TMA-2 (A) and its 4-position 
homologs MEM (B) and MPM (C).  Data are presented as group means in 2-min blocks. 
